Ann Zauber, PhD

Member, Attending Biostatistician
Pictured: Ann Zauber
Office Phone:
Johns Hopkins University

Current Research Interests

Dr. Zauber’s primary research focus is the impact of screening, surveillance, and chemoprevention on the national burden of colorectal cancer. Her work involves population based modeling to inform health policy and randomized clinical trials. Dr. Zauber leads a multi-center group of microsimulation modelers from the NCI consortium of the Cancer Intervention and Surveillance Modeling Network (CISNET) to address specific health policy questions in colorectal cancer screening. She conducted a decision analysis to inform the United States Preventive Services Task Force (USPSTF) in their recommendations on the age to begin, age to stop, and the intervals of re-testing for colorectal cancer screening for currently recommended tests. She also conducted cost-effectiveness analyses on CT colonography and stool DNA for colorectal cancer screening in the general population for the Centers for Medicare and Medicaid Services. The Annual Report to the Nation on Cancer (2010) featured colorectal cancer. Dr. Zauber led the special section in which microsimulation modeling showed that colorectal cancer screening contributed to more than 50% of the reduction in colorectal cancer over the past 25 years and that increased screening utilization can provide for continued reductions in mortality. Dr. Zauber is also the Principal Investigator for a multi-center randomized controlled trial of screening colonoscopy compared to a program of annual testing with fecal occult blood tests (National Colonoscopy Study) and a multi Principal Investigator on the NCI PROSPR consortium and co-investigator on a case control study of colonoscopy screening and colorectal cancer deaths. In addition she continues her assessment of risk factors for adenoma recurrence in the Adenoma Prevention with Celecoxib trial. She also has led the long term follow-up of the National Polyp Study demonstrating a large reduction in colorectal cancer with removal of adenomatous polyps.

Publications by Ann Zauber

Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Nov 4; 149(9):659-69. Epub 2008 Oct 6. Summary for patients in: Ann Intern Med. 2008 Nov 4; 149(9):I-44

Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010; 102(16):1238-52.

Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116(3):544-73.

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A. Contribution of screening and survival differences to racial disparities in colorectal cancer rates.  Cancer Epidemiol Biomarkers Prev. 2012; 21(5):728-36

Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366(8):687-96